Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review.

Autor: Mathiot L; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Baldini C; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Letissier O; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Hollebecque A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Bahleda R; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Gazzah A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Smolenschi C; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Sakkal M; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Danlos FX; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France.; Institut National de La Santé Et de La Recherche Médicale (INSERM) U1015, Villejuif, France.; Centre d'Investigations Cliniques Biothérapies Pour Une Immunisation in Situ (BIOTHERIS), INSERM, CIC1428, Villejuif, France., Henon C; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Beshiri K; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Goldschmidt V; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Parisi C; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Patrikidou A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Michot JM; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Marabelle A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Postel-Vinay S; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Bernard-Tessier A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Loriot Y; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France.; Institut National de La Santé Et de La Recherche Médicale (INSERM) U981, Villejuif, France., Ponce S; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France., Champiat S; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France.; Institut National de La Santé Et de La Recherche Médicale (INSERM) U1015, Villejuif, France.; Centre d'Investigations Cliniques Biothérapies Pour Une Immunisation in Situ (BIOTHERIS), INSERM, CIC1428, Villejuif, France., Ouali K; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif Cedex, France. kaissa.ouali@gustaveroussy.fr.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2024 Oct; Vol. 26 (10), pp. 1236-1248. Date of Electronic Publication: 2024 Jul 27.
DOI: 10.1007/s11912-024-01576-9
Abstrakt: Purpose of Review: Antibody-drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023.
Recent Findings: We hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach. This review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: